Hangzhou Adamerck Pharmlabs Inc.
Corporate brand
UnclaimedHangzhou-based innovative pharmaceutical company developing first-in-class small-molecule drugs, notably the clinical-stage candidate Aom0498.
Last updated September 26, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Hangzhou Adamerck Pharmlabs Inc. (Chinese: 杭州奥默医药股份有限公司; also known as Adamerck or AOMO Pharma) is a Chinese innovative pharmaceutical company headquartered in Hangzhou, Zhejiang Province. It traces its origins to Hangzhou Adamerck Pharmaceutical Technology Co., Ltd., established on 25 October 2000 near Mishixiang on Hushu South Road in Hangzhou. The company describes its mission as filling unmet clinical needs with original new drugs, and its stated goal is to develop and commercialize innovative products in China while building drug discovery, development and commercialization capabilities. Adamerck's business is centered on research and development of novel small-molecule therapeutics. Its best-known pipeline asset is Aom0498, a Class 1 new drug that progressed from preclinical work through NMPA and FDA regulatory interactions, Phase I–III clinical trials, and a new drug application in China. The company also lists Aom0319, Aom0315, Aom0304, Aom0499 and Aom0777 among its pipeline programs, several of which have entered clinical trials in Australia. Alongside prescription drug development, the company historically marketed a consumer product, Adamerck Lanyang tablets (奥默蓝养片), approved by Chinese regulators in 2006. The company operates through a group structure that includes Zhejiang Adamerck Biopharmaceutical Co., Ltd. (established 2004), Hangzhou Moyin Pharmaceutical Technology Co., Ltd. (2016), and overseas entities Adamolecule Inc. and AOMO PHARMA Inc. (both established 2015). It has been recognized as a National High-Tech Enterprise, hosts a Hangzhou Academician Workstation and a provincial high-tech enterprise R&D center, and has received funding under China's National Major New Drug Creation programs. It was listed on China's New Third Board (NEEQ) on 10 March 2015. Adamerck has raised angel, Series A and Series C financing, and in 2025 began construction of an industrialization base. It has been named a Hangzhou quasi-unicorn enterprise and included in lists such as the China Pharmaceutical Innovation Seed Enterprises Top 100 and the Future Healthcare 100. Its stated positioning is as an original-innovation drug developer addressing global clinical challenges, with a slogan rendered as "Tomorrow's medicine, benefiting life" (明日之药，康泽生命).
History
Hangzhou Adamerck Pharmlabs Inc. began as Hangzhou Adamerck Pharmaceutical Technology Co., Ltd., founded on 25 October 2000 at Mishixiang on Hushu South Road in Hangzhou. In 2004 the group expanded with the establishment of Zhejiang Adamerck Biopharmaceutical Co., Ltd., and it received the first batch of Hangzhou seed funding. In 2006 the company moved to Hangzhou Northern Software Park, and its Adamerck Lanyang tablets received CFDA approval for market launch. It obtained a Hangzhou industrial development fund in 2007. During the 2010s the company shifted decisively toward innovative drug development. In 2012 it received a project under the national "Major New Drug Creation" program and was designated a patent pilot enterprise in Gongshu District. In 2013 it established a Hangzhou Academician Workstation, was recognized as a Zhejiang technology-based SME, and obtained angel-round investment. In 2014 it was recognized as a National High-Tech Enterprise, established a Hangzhou enterprise high-tech R&D center, changed its name to Hangzhou Adamerck Pharmlabs Inc., and filed its Class 1 new drug Aom0498 with the NMPA. 2015 was a pivotal year: the company was listed on the New Third Board (NEEQ) on 10 March; Adamolecule Inc. was established on 16 April and AOMO PHARMA Inc. on 5 June; a Zhejiang provincial high-tech enterprise R&D center was designated; and on 16 December Aom0498 received NMPA approval, followed by an FDA Pre-IND meeting. In 2016 Aom0498 entered clinical trials as a Class 1.1 new drug and completed Phase I (with Phase I completion noted for 2017); the company received a "13th Five-Year Plan" national Major New Drug Creation project and established Hangzhou Moyin Pharmaceutical Technology Co., Ltd. In 2018 Aom0498 entered Phase II and completed Phase IIa, and a Zhejiang "characteristic APIs and formulations" innovation collaboration center was designated. In 2019 the company received a 2020 national Major New Drug Creation special project, was named a Hangzhou patent demonstration enterprise, and Aom0498 completed Phase IIb-1. In 2020 Aom0498 completed moderate Phase IIb-2 and deep Phase IIb trials, and the company completed a Series A financing round. In 2021 it moved into the Liangzhu Life Science Town and Aom0498 entered Phase III. In 2022 Aom0498 advanced into deep Phase III trials, Aom0319 and Aom0315 completed preclinical studies, and Aom0498 completed an FDA End-of-Phase 2 meeting. In 2023 Aom0498 completed Phase III trials, while Aom0319 and Aom0315 entered Phase I trials in Australia. In 2024 Aom0498's new drug marketing application was submitted to China's NMPA; Aom0319 and Aom0315 completed Australian Phase I trials; and Aom0499 completed a CDE Pre-NDA meeting. In 2025 the company completed a Series C financing round, began construction of an industrialization base, was named a Hangzhou quasi-unicorn enterprise, and was included among China's Top 100 pharmaceutical innovation seed enterprises. In 2026 it completed a Series C+ round; Aom0498 was approved for marketing in China and listed for procurement; Aom0498 and Aom0304 began Australian Phase IIa trials; Aom0304 applied for a China IND; the industrialization base topped out structurally; and the company was recognized by Forbes China as an industry-leading enterprise. The company's published roadmap extends into 2027–2028, covering international multi-center Phase III trials for Aom0498, approvals in Southeast Asian emerging markets, Phase IIb for Aom0304, Phase I–II for Aom0777, and GMP production lines at a wholly owned subsidiary's industrialization base.
- 2026
Completed Series C+ financing; Aom0498 approved for marketing and listed for procurement in China; Aom0498 and Aom0304 began Australian Phase IIa trials; Aom0304 applied for China IND; industrialization base topped out; recognized by Forbes China as industry-leading enterprise.
- 2025
Completed Series C financing; began construction of industrialization base; named Hangzhou quasi-unicorn enterprise; included in China Pharmaceutical Innovation Seed Enterprises Top 100.
- 2024
Aom0498 submitted new drug marketing application to NMPA; Aom0319 and Aom0315 completed Australian Phase I trials; Aom0499 completed CDE Pre-NDA meeting.
- 2023
Aom0498 completed Phase III trials; Aom0319 and Aom0315 entered Phase I trials in Australia.
- 2022
Aom0498 entered deep Phase III trials; Aom0319 and Aom0315 completed preclinical studies; Aom0498 completed FDA End-of-Phase 2 meeting.
- 2021
Officially moved into Liangzhu Life Science Town; Aom0498 entered Phase III trials.
- 2020
Aom0498 completed moderate Phase IIb-2 and deep Phase IIb trials; completed Series A financing.
- 2019
Received national Major New Drug Creation special project for 2020; Hangzhou patent demonstration enterprise designated; Aom0498 completed Phase IIb-1.
- 2018
Aom0498 entered Phase II and completed Phase IIa; Zhejiang 'characteristic APIs and formulations' innovation collaboration center designated.
- 2016
Class 1.1 new drug Aom0498 entered clinical trials and completed Phase I; received '13th Five-Year Plan' national Major New Drug Creation project; Hangzhou Moyin Pharmaceutical Technology Co., Ltd. established.
Products and positioning
Original-innovation pharmaceutical developer focused on first-in-class drugs that address unmet clinical needs in China and globally.
Aom0498
Class 1 innovative new drug candidate; progressed through NMPA and FDA interactions, Phase I–III trials, and a China new drug marketing application; approved for marketing in China in 2026 per company roadmap.
Aom0319
Pipeline candidate that completed preclinical studies in 2022 and entered Australian Phase I trials in 2023, completing them in 2024.
Aom0315
Pipeline candidate that completed preclinical studies in 2022 and entered Australian Phase I trials in 2023, completing them in 2024; received an Australian clinical approval (HREC/2022-11-1304).
Aom0304
Pipeline candidate that began Australian Phase IIa trials and applied for a China IND in 2026.
Aom0499
Pipeline candidate that completed a CDE Pre-NDA meeting in 2024.
Aom0777
Pipeline candidate that completed preclinical studies and was slated to start Phase I trials per the company's 2027 roadmap.
Adamerck Lanyang tablets (奥默蓝养片)
Consumer product approved by CFDA for market launch in 2006.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/hangzhou-adamerck-pharmlabs-inc-china · Editorial policy · How profiles are compiled